+ Watch AMRN
on My Watchlist
The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
Hemispheryx has Ampligen and Amarin has ethyl-EPA. Neither of these companies will let repeated trial failures prevent them from flogging their single pipeline products in new studies for new indications, relying on a never-ending supply of naive retail investors to suck up diluted equity. Amarin's MARINE and ANCHOR phase III trials of ethyl-EPA in hypertryglyceridemia won't be completed until 2011, and will likely turn out about as well as the phase III trials in dementia. In baby biotech, it's anyone's guess how high Amarin's share price might go awaiting those trial results. What seems much more likely is that Amarin will be sub 0.5 and headed for yet another reverse split once those results are in.
you've got some conviction.....
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions